NUTRITIONAL PRIMARY PREVENTION OF TYPE I DIABETES IN CHILDREN

儿童 I 型糖尿病的营养一级预防

• 批准号: 7603388
• 负责人: Neil H. White
• 金额: $ 0.72万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603388
• 关键词: Affect; Autoimmunity; Breast Feeding; Cattle; Child; Computer Retrieval of Information on Scientific Projects Database; Development; Diabetes Mellitus; Double-Blind Method; First Degree Relative; Funding; Genotype; Glucose Intolerance; Grant; Immunologic Markers; Incidence; Institution; Insulin-Dependent Diabetes Mellitus; Islet Cell; Islets of Langerhans; Life; Mothers; Newborn Infant; Nutritional; Primary Prevention; Randomized; Randomized Controlled Trials; Research; Research Personnel; Resources; Risk; Source; United States National Institutes of Health; Weaning; base; casein hydrolysate

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a multinational, multicenter, double-blinded, randomized controlled trial to determine whether weaning to a casein hydrolysate formula during at least the first 6 months of life reduces the incidence of type 1 diabetes in genetically susceptible children. Newborn infants, who have an increased risk-associated HLA genotype and an affected first degree relative, will be randomly assigned to receive either a cow's mild-based formula (Enfamil) or a casein hydrolysate formula (Nutramigen) for the first 6-8 months of life. The mother's breast feeding wishes will not be interrupted. Subjects will be followed for 5 years (10 years if funding allows) for the presence of immunologic markers of islet cell autoimmunity and the development of diabetes and/or glucose intolerance.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 中心，不一定是研究者的机构。 这是一项跨国、多中心、双盲、随机对照试验，旨在确定至少在生命的前 6 个月内断奶使用酪蛋白水解产物配方奶粉是否可以降低遗传易感儿童 1 型糖尿病的发病率。 具有增加的风险相关 HLA 基因型和受影响的一级亲属的新生儿将被随机分配在前 6-8 个月内接受奶牛温和配方奶粉 (Enfamil) 或酪蛋白水解产物配方奶粉 (Nutramigen)的生活。 妈妈的母乳喂养愿望不会被打断。 受试者将被跟踪 5 年（如果资金允许，则为 10 年），以了解胰岛细胞自身免疫的免疫标记物的存在以及糖尿病和/或葡萄糖不耐受的发展。